Teva Pharmaceutical Industries Ltd. ADR-2.74% $19.5B ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. GSK's Beat-and-Raise ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...

GSK has shifted towards a global marketing model influenced by a Netflix-style approach that aims to match content to the person receiving it. Richard Staines heard about this new strategy at the ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion pounds ($2.5 billion) share ...

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...

GSK shares jumped 5.9% as it lifted its 2031 sales target to over £40 billion. The company plans a £2 billion share buyback over the next 18 months. GSK reported that its total sales grew by 3% ...

Vivian Wan / Bloomberg via Getty Images GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...